IE85880B1 - A drug delivery device for providing local analgesia, local anesthesia or nerve blockade - Google Patents
A drug delivery device for providing local analgesia, local anesthesia or nerve blockade Download PDFInfo
- Publication number
- IE85880B1 IE85880B1 IE2007/0220A IE20070220A IE85880B1 IE 85880 B1 IE85880 B1 IE 85880B1 IE 2007/0220 A IE2007/0220 A IE 2007/0220A IE 20070220 A IE20070220 A IE 20070220A IE 85880 B1 IE85880 B1 IE 85880B1
- Authority
- IE
- Ireland
- Prior art keywords
- collagen
- delivery device
- local
- drug delivery
- bupivacaine
- Prior art date
Links
- 230000036592 analgesia Effects 0.000 title claims abstract description 45
- 201000008125 pain agnosia Diseases 0.000 title claims abstract description 45
- 238000002690 local anesthesia Methods 0.000 title claims abstract description 37
- 229940089114 Drug Delivery Device Drugs 0.000 title claims abstract description 31
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 44
- 230000003444 anaesthetic Effects 0.000 claims abstract description 41
- 102000008186 Collagen Human genes 0.000 claims abstract description 40
- 108010035532 Collagen Proteins 0.000 claims abstract description 40
- 229960005188 collagen Drugs 0.000 claims abstract description 40
- 229920001436 collagen Polymers 0.000 claims abstract description 40
- 239000011159 matrix material Substances 0.000 claims abstract description 32
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229940035674 ANESTHETICS Drugs 0.000 claims abstract description 22
- 239000003193 general anesthetic agent Substances 0.000 claims abstract description 22
- 102000013373 Fibrillar Collagens Human genes 0.000 claims abstract description 20
- 108060002894 Fibrillar Collagens Proteins 0.000 claims abstract description 20
- -1 amino ester Chemical class 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 11
- LEBVLXFERQHONN-UHFFFAOYSA-N Bupivacaine Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 48
- 229960003150 bupivacaine Drugs 0.000 claims description 48
- 239000000515 collagen sponge Substances 0.000 claims description 40
- 238000009802 hysterectomy Methods 0.000 claims description 26
- 102000012422 Collagen Type I Human genes 0.000 claims description 21
- 108010022452 Collagen Type I Proteins 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 15
- 239000000651 prodrug Substances 0.000 claims description 13
- 229940002612 prodrugs Drugs 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 206010002091 Anaesthesia Diseases 0.000 claims description 11
- 229960001050 Bupivacaine Hydrochloride Drugs 0.000 claims description 11
- 230000037005 anaesthesia Effects 0.000 claims description 11
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 7
- 229960004194 lidocaine Drugs 0.000 claims description 7
- LEBVLXFERQHONN-INIZCTEOSA-N Levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims description 6
- 229960004288 levobupivacaine Drugs 0.000 claims description 6
- 229960001549 Ropivacaine Drugs 0.000 claims description 5
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N Ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims description 5
- 229960002409 mepivacaine Drugs 0.000 claims description 5
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 5
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 claims description 4
- MVFGUOIZUNYYSO-UHFFFAOYSA-N Prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 4
- 210000003491 Skin Anatomy 0.000 claims description 4
- GOZBHBFUQHMKQB-UHFFFAOYSA-N Trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 claims description 4
- 229960003831 articaine Drugs 0.000 claims description 4
- 229960001807 prilocaine Drugs 0.000 claims description 4
- 229950002569 trimecaine Drugs 0.000 claims description 4
- 210000004303 Peritoneum Anatomy 0.000 claims description 3
- 238000002350 laparotomy Methods 0.000 claims description 3
- HUCIWBPMHXGLFM-UHFFFAOYSA-N bupivacaine hydrochloride hydrate Chemical compound O.[Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C HUCIWBPMHXGLFM-UHFFFAOYSA-N 0.000 claims 4
- 239000000126 substance Substances 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 description 42
- 230000036407 pain Effects 0.000 description 40
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 23
- 229960005181 morphine Drugs 0.000 description 23
- 229930014694 morphine Natural products 0.000 description 23
- 238000000034 method Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 238000001356 surgical procedure Methods 0.000 description 18
- 239000003814 drug Substances 0.000 description 15
- 208000004550 Postoperative Pain Diseases 0.000 description 14
- 208000000399 Procedural Pain Diseases 0.000 description 14
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 14
- 230000003187 abdominal Effects 0.000 description 13
- 238000001764 infiltration Methods 0.000 description 13
- 229940079593 drugs Drugs 0.000 description 12
- 230000001954 sterilising Effects 0.000 description 12
- 238000004659 sterilization and disinfection Methods 0.000 description 12
- 200000000019 wound Diseases 0.000 description 12
- 241000283690 Bos taurus Species 0.000 description 10
- 230000000007 visual effect Effects 0.000 description 9
- 230000000202 analgesic Effects 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- SIEYLFHKZGLBNX-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 description 7
- 210000002435 Tendons Anatomy 0.000 description 7
- 230000002980 postoperative Effects 0.000 description 7
- 210000004369 Blood Anatomy 0.000 description 6
- 210000003169 Central Nervous System Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000007429 general method Methods 0.000 description 5
- 239000003589 local anesthetic agent Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229910001220 stainless steel Inorganic materials 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000002381 Plasma Anatomy 0.000 description 4
- 238000006065 biodegradation reaction Methods 0.000 description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 4
- 229960001259 diclofenac Drugs 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000002035 prolonged Effects 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 210000003815 Abdominal Wall Anatomy 0.000 description 3
- 210000001361 Achilles Tendon Anatomy 0.000 description 3
- 102100004057 CYP3A4 Human genes 0.000 description 3
- 101710007540 CYP3A4 Proteins 0.000 description 3
- 208000002173 Dizziness Diseases 0.000 description 3
- 241001602876 Nata Species 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 210000002700 Urine Anatomy 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 238000001949 anaesthesia Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000271 cardiovascular Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 229920001684 low density polyethylene Polymers 0.000 description 3
- 239000004702 low-density polyethylene Substances 0.000 description 3
- 230000003533 narcotic Effects 0.000 description 3
- 230000003364 opioid Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001953 sensory Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- BTXNYTINYBABQR-UHFFFAOYSA-N Hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 230000035888 Maximum plasma concentration Effects 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 239000004698 Polyethylene (PE) Substances 0.000 description 2
- 206010038678 Respiratory depression Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000003197 catalytic Effects 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000015201 grapefruit juice Nutrition 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002045 lasting Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000000153 supplemental Effects 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- QJVHTELASVOWBE-AGNWQMPPSA-N (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 QJVHTELASVOWBE-AGNWQMPPSA-N 0.000 description 1
- VHVPQPYKVGDNFY-TUJWMRSMSA-N 2-[(2S)-butan-2-yl]-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-TUJWMRSMSA-N 0.000 description 1
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 230000035533 AUC Effects 0.000 description 1
- 210000000683 Abdominal Cavity Anatomy 0.000 description 1
- 208000005298 Acute Pain Diseases 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N Amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 Amiodarone Drugs 0.000 description 1
- 241001535291 Analges Species 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 208000008784 Apnea Diseases 0.000 description 1
- 206010002974 Apnoea Diseases 0.000 description 1
- 206010003119 Arrhythmia Diseases 0.000 description 1
- 229940098164 Augmentin Drugs 0.000 description 1
- 229960005274 Benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N Benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- NNUSCVFWUPARGJ-UHFFFAOYSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=NC(CC=2[C](C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N=2)CCC(O)=O)=C(CCC(O)=O)[C]1C NNUSCVFWUPARGJ-UHFFFAOYSA-N 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 208000006218 Bradycardia Diseases 0.000 description 1
- 102000025380 C-Reactive Protein Human genes 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N Carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 206010007515 Cardiac arrest Diseases 0.000 description 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229960002023 Chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N Chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 230000037242 Cmax Effects 0.000 description 1
- 206010010276 Conduction disease Diseases 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 229940109239 Creatinine Drugs 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N Cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Epinat Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 210000003195 Fascia Anatomy 0.000 description 1
- 229960002428 Fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N Fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 206010018847 Haematological disease Diseases 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 210000003709 Heart Valves Anatomy 0.000 description 1
- 240000008526 Hypericum perforatum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N Indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N Ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 230000035832 Lag time Effects 0.000 description 1
- 230000035648 Lag-time Effects 0.000 description 1
- 206010024190 Leiomyosarcomas Diseases 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 206010024855 Loss of consciousness Diseases 0.000 description 1
- 208000007106 Menorrhagia Diseases 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N Methadone Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 210000004251 Milk, Human Anatomy 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N Nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N Nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029151 Nephropathy Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 229940005483 OPIOID ANALGESICS Drugs 0.000 description 1
- 229940052264 Other local anesthetics in ATC Drugs 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 229960002036 Phenytoin Drugs 0.000 description 1
- 210000002826 Placenta Anatomy 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N RIFAMPICIN Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 206010038428 Renal disease Diseases 0.000 description 1
- 229940081190 Rifampin Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N Ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N Saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229960001852 Saquinavir Drugs 0.000 description 1
- 206010039911 Seizure Diseases 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 235000002197 St. John’s wort Nutrition 0.000 description 1
- 210000004304 Subcutaneous Tissue Anatomy 0.000 description 1
- 230000037034 TERMINAL HALF LIFE Effects 0.000 description 1
- 229960002372 Tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N Tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 230000035624 Tlag Effects 0.000 description 1
- 230000035852 Tmax Effects 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N Troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 208000009935 Visceral Pain Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000007486 appendectomy Methods 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000001451 cardiotoxic Effects 0.000 description 1
- 231100000457 cardiotoxic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- ZPUCINDJVBIVPJ-BARDWOONSA-N cocaine Natural products O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001815 facial Effects 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960003029 ketobemidone Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001483 mobilizing Effects 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 230000000399 orthopedic Effects 0.000 description 1
- 125000000963 oxybis(methylene) group Chemical group [H]C([H])(*)OC([H])([H])* 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000505 parietal peritoneum Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002215 polytrimethylene terephthalate Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001020 rhythmical Effects 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
Abstract
ABSTRACT The invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matiix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one diug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.
Description
TITLE A drug delivery device for providing local analgesia, local anesthesia or nerve blockade Field of the Invention
[0001] The present invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade and a method for providing local analgesia, local anesthesia or nerve blockade in a human or animal in need thereof.
Related Background Art
[0002] Post-surgical pain is a complex response to tissue trauma during surgery that stimulates hypersensitivity of the central nervous system. Post-operative pain increases the possibility of post—surgical complications, raises the cost of medical care and, most importantly, interferes with recovery and return to normal activities of daily living.
Management of post-surgical pain is a basic patient right. When pain is controlled or removed, a patient is better able to participate in activities such as walking or eating, which will encourage his or her recovery. Patients will also sleep better, which aids the healing process.
[0003] Collagen sponges have been used globally as hemostatic agents. The present inventors have developed a drug delivery device in the optional form of a collagen sponge impregnated with at least one anesthetic such as bupivacaine hydrochloride, intended for use in the management of post-operative pain following surgery including, but not limited to, moderate/major orthopedic, abdominal, gynecological or thoracic surgery. The at least one anesthetic is contained, in one embodiment, within a collagen matrix comprised of fibrillar collagen, such as Type I collagen purified from bovine Achilles tendons.
[0004] Bupivacaine, introduced in 1963, is a widely used amide local anesthetic with a prolonged duration of action. It affects sensory nerves more than motor nerves and can also be used to provide several days’ effective analgesia without motor blockade.
[0005] Bupivacaine is characterized by its longer duration and slow onset compared with other local anesthetics. Bupivacaine is markedly cardiotoxic. Systemic exposure to excessive quantities of bupivacaine mainly result in central nervous system (CNS) and cardiovascular effects - CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations. CNS effects may include CNS excitation (nervousness, tingling around the mouth, tinnitus, tremor, dizziness, blurred vision, seizures) followed by depression (drowsiness, loss of consciousness, respiratory depression and apnea). Cardiovascular effects include hypotension, bradycardia, arrhythmias, and/or cardiac arrest — some of which may be due to hypoxemia secondary to respiratory depression.
Incisional local anesthesia
[0006] Wound infiltration with local anesthesia is used widely for postoperative pain: it is simple, safe and low cost. However, it is unclear whether differences in surgical procedure or whether visceral components influence efficacy. Incisional anesthesia includes infiltration, topical administration or instillation of local anesthetic at the following sites: skin, subcutaneous tissue, fascia, muscle and/or the parietal peritoneum. However, in spite of widespread use, wound infiltration is still inconsistently and randomly used by many surgeons and anesthetists.
[0007] Although there is a great number of papers and reviews on this topic, there is little consensus available on when and afler which surgical procedures, incisional local anesthesia may provide clinically relevant post-operative pain alleviation. Of special interest may be to what extent differences in surgical procedure or involvement of visceral components influence efficacy. Incisional local anesthesia has been studied in a broad range of surgical models, including abdominal hysterectomy, inguinal hemiotomy, open cholecystectomy, appendectomy, Caesarean section and other laparotomy procedures. A laparotomy is a surgical maneuver involving an incision through the abdominal wall to gain access into the abdominal cavity.
[0008] The anesthetics assessed for post-operative pain relief include lidocaine, bupivacaine, ropivacaine and mepivacaine, which all belong to the amino amide anesthetic group. On review of the data on the use of incisional anesthesia in hysterectomy surgery, conflicting results have been obtained. In a study by Sinclair et al, 1996, 500mg of lidocaine administered as an aerosol subcutaneously caused a significant reduction of approximately 50% in pain scores and supplementary analgesic consumption during the first 24 hours of the study, but not later. In a study by Hannibal and co-workers, 0.25% bupivacaine solution 45ml infiltrated subfascially and subcutaneously caused a 50% reduction in analgesic consumption but not in pain scores or time to first analgesic request.
In contrast, two studies evaluating subcutaneous infiltration of bupivacaine solution compared with no treatment showed no improvement in analgesia (Cobby et al, 1997, Victory et al, 1995). [0009} Studies in other models have shown short-term analgesic effects over 4 to 7 hours.
In three studies on Caesarean section, 0.25% or 0.5% bupivacaine 20ml caused a 20-50% reduction in analgesic consumption but this effect only lasted for 4 hours. In another study in upper abdominal surgery, only a slight reduction in daily morphine administration (supplemental intramuscular morphine) (10mg) was noted and a reduction in visual analogue scoring (VAS) only during mobilization was recorded (50mm) (Bartholdy et al, 1994). In a review of incisional anesthesia for the control of post-operative pain, Meiiniche et al (1998) assessed 26 studies involving over 1200 patients in surgeries using abdominal incision. The results showed a consistent statistical and clinical effect of incisional anesthesia in herniotomy surgery, although the analgesia was short-lived (2-7 hours).
However, in the other surgical models evaluated including hysterectomy the results were variable between studies.
[0010] Of the 26 studies evaluated (Moiniche et al, 1998), eight were unequivocally negative. Although the majority of studies showed significant differences in at least one pain measure, several were of questionable clinical importance and the authors were surprised that local anesthesia was not associated with more consistent positive results.
The authors also noted the importance in the technique used and site to administer the anesthetics. [001l} Since the 1998 review, surgical wound infiltration trials have continued to be performed and published as the practice remains relatively common despite the lack of strong evidence. For example, a group in Leicester, UK, have published two hysterectomy trials (Klein et al, 2000 and Ng et al, 2002), which at best have concluded a duration of effect only up to 4 hours post-operatively.
[0012] In contrast, trials where bupivacaine has been instilled post-operatively on a continuous or intermittent basis Via an indwelling catheter have tended to prove much more successful and effective. Gupta et al (2004) compared an infusion of normal saline against an infusion of 0.25% levobupivacaine (l2.5mg/hr) over 24 hours and showed a significant reduction in incisional pain, deep pain and pain on coughing at 1-2 hours post hysterectomy surgery. Total ketobemidone (PCA narcotic) was significantly reduced over the 4-24 hour period and the authors conclude that the intraperitoneal infusion of levobupivacaine has significant opioid sparing effects after elective abdominal hysterectomy.
[0013] The apparent efficacy of anesthetic infusions explains the widespread use of ambulatory pain pumps, such as I-Flow’s ON-Q® Painbuster. However, such continuous infusion devices use much higher total doses of bupivacaine (between 2.5mg/hr and 50mg/hr with a maximum dosing duration of 5 and 2 days, respectively) and of course are less convenient than a biodegradable implant. The in-dwelling catheter used in the pain pump system can lead to infection and must be removed by a physician or nurse. In contrast, a drug delivery device such as the bupivacaine-collagen sponge provides, as will be demonstrated hereunder, effective, long lasting analgesia but at a dose only equivalent to a once-off bolus infiltration of the wound.
[0014] In the present invention, this long lasting analgesia is achieved through the use of a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected fiom the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration. Accordingly, the invention provides, in a first aspect, a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day afler administration.
[0015] It is hypothesized that such drug delivery devices as the bupivacaine-collagen sponge will afford post-operative pain management to patients without adverse effects associated with toxicity from the collagen sponge or elevated systemic anesthetic (such as bupivacaine) levels. It is hypothesized that such drug delivery devices as the bupivacaine- collagen sponge will provide local pain relief to patients for up to 48 or 72 hours at the surgical site and reduce the patient’s demand for systemic analgesia and the associated adverse effects.
SUMMARY OF THE INVENTION
[0016] The present invention is directed to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration. The present invention is directed, in an optional embodiment, to a biodegradable, leave-behind device.
BRIEF DESCRIPTION OF THE FIGURES
[0017] Figure 1 shows, schematically, a flow diagram for the production of collagen.
[0018] Figure 2 shows, schematically, a flow diagram for the production of a drug delivery device in the optional form of a bupivacaine-collagen sponge.
DETAILED DESCRIPTION OF THE INVENTION
[0019] This invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day afier administration.
[0020] In a second aspect, the invention relates to a method for providing local analgesia, local anesthesia or nerve blockade in a human or animal in need thereof, the method comprising administering at a site in a human or animal in need thereof a drug delivery device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.
[0021] Optionally, in the device or method of the invention, the at least one drug ' substance is present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about two days after administration.
[0022] Optionally, in the device or method of the invention, the at least one drug substance is present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about three days, fiirther optionally at least four days, afier administration.
[0023] Optionally, in the device or method of the invention, the at least one drug substance is an amino amide anesthetic selected from the group comprising Bupivacaine, Levobupivacaine, Lidocaine, Mepivacaine, Prilocaine, Ropivacaine, Articaine, Trimecaine and their salts and prodrugs. Further optionally, in the device or method of the invention, the at least one drug substance is an amino amide anesthetic selected from bupivacaine and salts and prodrugs thereof.
[0024] Optionally, in the device or method of the invention, the fibrillar collagen matrix is a Type I collagen matrix.
[0025] Optionally, in the device or method of the invention, the fibrillar collagen matrix is a Type I collagen matrix and the at least one drug substance is an amino amide anesthetic selected from bupivacaine and salts and prodrugs thereof. Further optionally, the drug delivery device comprises a plurality of collagen sponges, each collagen sponge containing about 3.6 to about 8.0mg/cm3 type I collagen and about 2.0 to about 6.Omg/cm3 bupivacaine hydrochloride. Still further optionally, the drug delivery device comprises a plurality of collagen sponges, each collagen sponge containing about 5.6mg/cm3 type I collagen and about 4.0mg/cm3 bupivacaine hydrochloride.
[0026] Optionally, in the method of the invention, the method is for providing local analgesia, local anesthesia or nerve blockade in a human following laparotorny.
[0027] Optionally, in the method of the invention, the method is for providing local analgesia, local anesthesia or nerve blockade in a human following hysterectomy.
[0028] Optionally, in the method of the invention, the drug delivery device comprises a plurality of collagen sponges and wherein one sponge is divided between areas in the surgical vault, one sponge is divided and placed across the incision in the peritoneum and one sponge is divided and placed between the sheath and skin around the incision.
Drug Substance
[0029] Suitable drug substances comprise amino amide anesthetics and amino ester anesthetics and their salts, hydrates and prodrugs. Such drug substances include, but are not limited to, amino amides such as Bupivacaine, Levobupivacaine, Lidocaine, Mepivacaine, Prilocaine, Ropivacaine, Articaine, Trimecaine and their salts and prodrugs; and amino esters such as Benzocaine, Chloroprocaine, Cocaine, Procaine, Tetracaine and their salts and prodrugs. Bupivacaine, and its salts and prodrugs is an optional drug substance. Mixtures of amino amides are contemplated, as are mixtures of amino esters.
Mixtures of amino amides and amino esters are also contemplated.
[0030] Bupivacaine Hydrochloride (HCl) is a potent anesthetic and can produce moderate to prolonged anesthesia. When compared to other available amino amide anesthetics, the relatively longer duration of action coupled with its action on sensory block, rather than motor-block, permits prolonged anesthesia for post-operative pain. Bupivacaine HCl can provide effective sensory block and analgesia for several days. Bupivacaine HCl is indicated for moderate to prolonged local anesthesia and, therefore, treatment of moderate to acute pain.
[0031] Toxicity related to bupivacaine is caused by high systemic levels and are characterized by numbness of the tongue, light-headedness, dizziness and tremors, followed by convulsions and cardiovascular disorders.
[0032] The pharmacokinetics and pharmacodynamics of bupivacaine are well understood.
Bupivacaine is about 95% bound to plasma proteins. Reported half-lives are from 1.5 to .5 hours in adults and about 8 hours in neonates. It is metabolized in the liver and is excreted in the urine, principally as metabolites with only 5 to 6% as unchanged drug.
Bupivacaine is distributed into breast milk in small quantities. It crosses the placenta but the ratio of fetal to maternal concentrations is relatively low. Bupivacaine also diffuses into the cerebrospinal fluid (CSF).
[0033] The toxic threshold for bupivacaine plasma concentrations is considered to lie in the range of 2 to 4 micrograms/ml; and, in the US, the maximum single recommended dose for anhydrous bupivacaine hydrochloride is 175 mg. Measurement of bupivacaine levels in the clinical setting needs to demonstrate dosing and systemic levels within these safety parameters. Thus, when it is intended to administer bupivacaine, whether in one or several collagen sponges, it is suggested that the total dose should be no more than about 250 mg, optionally no more than about 200 mg, for anhydrous bupivacaine hydrochloride.
Collagen
[0034] Fibrillar collagen from different sources may be used including commercially available fibrillar collagen, for example, biomedical collagen from Devro Biomedical Collagen, Australia. Currently there are five known types of fibrillar collagen; Type I, II, III, V and XI. Alternatively, collagen can be extracted from tendons or hides of different animals, including horses, cattle, sheep and pigs. The attention of the skilled reader is drawn to Gelse et al (Advanced Drug Delivery Reviews 55 (2003)l 531-1546), the whole contents of which are incorporated herein by reference for further details on the various types of collagen. The present inventors have used a bovine-derived collagen Type 1 for the manufacture of bupivacaine-collagen sponges. Equine-derived collagen Type 1 is also suitable for use in the present invention, as are fibrillar collagen such as type 1 collagen from pigs and sheep. Type I collagen is a connective tissue extracted from animal tendons and other sources; in this case, the collagen is derived from bovine tendons. The Type I collagen consists of three approximately 1,050 amino-acid—long polypeptide chains, two alpha-1 chains, and one alpha-2 chain. These are coiled to form a right-hand helix (known as a triple helix) around a common axis. The rod-shaped molecule has a length of 2900 Angstrom, a diameter of 14 Angstrom and a molecular weight of approx. 300,000 Daltons.
Method of Manufacture
[0035] The following general method of manufacture refers to type I collagen being produced from bovine tendons. However, alternative sources of fibrillar collagen such as alternative sources of type I or III collagen may be used in place of this methodology, without departing from the scope of the teaching of this invention.
[0036] The following general method of manufacture refers to bupivacaine as the drug substance. It will be appreciated that alternative drug substance(s), or additional drug substance(s) (i.e. additional to bupivacaine), may be used in place of bupivacaine alone, without departing from the scope of the teaching of this invention.
Collagen
[0037] Production of Type 1 Collagen from Bovine Tendons : The collagen is extracted from bovine Achilles tendon. During the manufacturing process, bovine tendons are first treated with 1N sodium hydroxide (N aOH) to clean and purify the material and to deplete the fat content followed by neutralization with IN HC1. This step is followed by treatment with 0.9% sodium chloride (NaCl) solution to remove low molecular weight soluble components of the collagen. A treatment with hydrogen peroxide solution ensures bleaching of the tendons. H
[0038] Reduction of the particle size of the collagen material is followed by ferrnentative breakdown using pepsin. Treatment with pepsin is used to degrade contaminating serum protein components, primarily bovine serum albumin and causes the detachment of non~ helical portions of the collagen molecule (telopeptides). Afler filtration. precipitation of tlie collagen is accomplished by means of manipulation of the pH (from acidic pH to neutral pH). The fibrillar Type I collagen material is finally precipitated out of solution, washed again with distilled water to remove residual pepsin and then concentrated by means of centrifugation. The production process is outlined in Figure 1.
Bupivaeaine Collagen Sponge - Method of Manufacture
[0039] Figure 2 is a flow diagram representing the production of the bupivacaine-collagen sponge. The skilled reader will appreciate that other drug substance(s) may be used in place of, or in addition to, the bupivacaine.
Compounding Process and Equipment
[0040] The fibrillar Type 1 collagen material prepared as in Figure 1 is added to pre- heated water (below 42°C) in a stainless steel (SS) vessel. Collagen swelling and subsequent dispersion formation is afforded by the use of a high-shear homogenizer. The homogenizer employed possesses a rotor-stator head that is designed to create high shear forces by pulling the collagen material through the rotating homogenizer head and forcing it against the proximal stationary stator head. It is this design that facilitates the high shear forces required to separate the fibrous collagen mass at the beginning of dispersion preparation.
[0041] Following completion of collagen dispersion formation, the dispersion is transferred to a closed heated jacketed vessel for final compounding. The jacket temperature is maintained at 36 - 38°C.
[0042] The or each drug substance (such as bupivacaine HCI) raw material is first dissolved in a portion of water at room temperature and is then introduced into the heat- jacketed SS vessel under low shear mixing to achieve homogeneity in the drug—loaded collagen dispersion. The collagen/ bupivacaine dispersion is a free flowing opaque white to off-white liquid.
[0043] The dispersion is subsequently freeze—dried yielding a sponge containing, in one embodiment, 5.6mg/cm3 of collagen and 4.0mg/cm3 of bupivacaine HCl in a final lyophilized 5cm x 5cm product. Other product sizes can also be manufactured including a 10cm X 10cm sponge also containing, in an embodiment, 5.6mg/cm3 of collagen and 4.0mg/cm3 of bupivacaine HCl.
Filling/Lyophilization Process and Equipment
[0044] The collagen/drug dispersion is filled into appropriately sized lyophilization molds or blister trays for freeze-drying and the filling process is performed using a positive displacement pump. The pump is valve-less, has ceramic pistons and works on the principle of positive displacement.
[0045] Upon completion of tray filling, the filled moulds or blister trays are placed into the lyophilizer. Thermocouples are placed both in product and on shelves and a conductivity probe is also employed to provide in-process feedback on process temperatures and conductivity. The lyophilization process cycle used for the bupivacaine- collagen sponge involves freezing down to a temperature of -38°C over 3.5 hours, followed by drying to a temperature of 30°C over 14.5 hours.
Ethylene Oxide (EtO) Sterilization Process
[0046] The lyophilized sponge is packed into suitable packaging material, which may comprise of a sealed polyethylene blister or low density polyethylene (LDPE) sachet in an outer pouch consisting of polyethylene/LDPE laminate or aluminum foil. The product is then subjected to terminal sterilization, which can be gas-mediated ethylene oxide sterilization or radiation (gamma or electron beam). In the preferred embodiment, sterilization by ethylene oxide gas has been selected.
[0047] Ethylene oxide (C2H4O) is a gas at operating temperature and sterilizes via its action as a powerfisl alkylating agent. Under the correct conditions, cellular constituents of organisms such as nucleic acid complexes, functional proteins and enzymes will react with ethylene oxide, causing the addition of alkyl groups. As a result of the alkylation, cell reproduction is prevented and cell death ensues. Specific processing conditions and parameters must be met to achieve this effect within the target product; including but not limited to, acceptable concentration of ethylene oxide in the chamber and a minimum water activity level within the organism. The process is essentially a chemical reaction and is therefore temperature dependent; the rate of reaction increases with temperature. The optimum temperature is within the range of 30 and 40°C. These properties define the key characteristics of the ethylene oxide sterilization process.
[0048] The process is dependent on the water content existing in the sponges and a consistent range of moisture content is achieved by equilibration of the product with atmospheric humidity prior to sterilization. An optimum water content is not less than 9%.
The product is loaded into stainless steel wire mesh baskets and placed into the stainless steel sterilizer chamber using a defined loading pattern. The sterilization chamber is then evacuated to remove air and ethylene oxide is introduced until the required concentration is achieved.
[0049] Product is held under these conditions for a defined period and, on completion of the pre-determined dwell period, ethylene oxide from the chamber is exhausted to the atmosphere via catalytic converters. These units ensure catalytic conversion of ethylene oxide to carbon dioxide and water with high efficiency. The sterilization chamber and its contents are then repeatedly flushed with air to remove the remaining ethylene oxide from the chamber. After completion of post sterilization flushing, the product is transferred to a holding area for longer term aeration. This phase of the process serves to further scavenge low level residual ethylene oxide firorn the product and packaging. The product is held at room temperature until the limits for ethylene oxide derivative residues have been reached.
Alternative Sterilization Process and Equipment
[0050] Radiation sterilization including gamma and electron beam may be used instead of the E0 sterilization process mentioned above.
[0051] The bupivacaine-collagen sponge manufactured under this general method of manufacture is a drug-delivery system composed of a Type I collagen matrix containing the amide local anesthetic bupivacaine HCl. The release of bupivacaine is primarily by dissolution and diffusion from the porous matrix with the collagen sponge acting as an inert delivery system.
Hysterectomies
[0052] Hysterectomy is the second most common surgery among women in the United States (US). According to the National Center For Health Statistics, there were 617,000 hysterectomies performed in the US in 2004. Indications for hysterectomy include benign tumors, such as fibroids, heavy periods, painful periods and chronic pelvic pain. The most common route for performing hysterectomy is through an incision in the abdominal wall; however, about 20% are performed vaginally. Laparoscopic-assisted vaginal hysterectomy is performed when warranted.
Pain Control in Hysterectomies
[0053] Effective postoperative pain management is important in ensuring that surgical subjects have a smooth and successfiil recovery after their operation. Pain after abdominal hysterectomy can be multifactorial. Incision pain, pain from deeper (visceral) structures, and particularly, dynamic pain, such as during straining, coughing, or mobilizing, can be quite severe. In one study, the authors found that visceral pain dominated during the first 48-hours after hysterectomy (Leung, 2000).
[0054] Morphine is often used via patient-controlled analgesic (PCA) pumps to control post-operative pain, but the large quantities required can lead to fatigue, nausea and vomiting, as well as the inability to mobilize because of drowsiness. Subjects usually require PCA for at least 24-hours, after which they receive oral analgesic drugs. The average postoperative narcotic consumption during the first 24-hours varies from 35 to 62mg (Gupta, 2004) and the average postoperative morphine consumption using bupivacaine infiltration in both and superficial layers of the wound after abdominal hysterectomy was 54mg (Klein et al, 2000) and 44mg (N g et al, 2002).
Collagen Products
[0055] The properties of insoluble and soluble collagen have led to its use in a variety of medical applications ranging from heart valves to dermal implants. Soluble collagen can be used to produce biodegradable or non-biodegradable materials that give useful mechanical properties and biocompatibility.
[0056] Soluble collagen can be cross-linked to produce semi-permanent, non-absorbable implants that can be delivered by intradermal injection such as those used in facial aesthetics. These were first approved by the US Food and Drug Administration (FDA) in the 19803.
[0057] The present collagen matrix can be a localized drug delivery system based on a fibrillar (Type I or Type III) collagen matrix, optionally derived from bovine Achilles tendons. The products are manufactured as a lyophilized sponge.
[0058] Embodiments of the invention will [now be demonstrated by reference to the above- mentioned General Method of Manufacture, which is then exemplified by reference to the Clinical Study described hereunder. '
[0059] Specific embodiments of the invention will now be demonstrated by reference to the following general methods of manufacture and examples. It should be understood that these examples are disclosed solely by way of illustrating the invention and should not be taken in any way to limit the scope of the present invention.
EXAMPLES: Clinical Study
[0060] The effective relief of pain is of paramount importance to those treating patients undergoing surgery. This should be achieved for humanitarian reasons, but there is now evidence that pain relief has significant physiological benefit. Not only does effective pain relief mean a smoother postoperative course with earlier discharge from hospital, but it may also reduce the onset of chronic pain syndromes. Topical or local administration of anesthetics directly at the surgical site has the advantage of producing high local anesthetic concentrations, while minimizing potentially toxic systemic concentrations.
[0061] The bupivacaine—col1agen sponge is highly malleable and can be applied directly, rolled or folded, giving the surgeon great flexibility in terms of application in wounds scheduled for closure.
[0062] Patients received three 5cm x S cm (X 0.5cm thick) sponges; one sponge divided between areas in the surgical vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision. Each sponge contained 50mg of bupivacaine hydrochloride, giving a total dose of 150mg per patient.
[0063] This was a single dose, open-label, prospective clinical study to investigate drug delivery devices in the form of a bupivacaine-collagen sponge in patients following hysterectomy, for pain control in hysterectomy. The patients were scheduled to receive a hysterectomy in the absence of uterine adenocarcinorna, cervical cancer, leiomyosarcoma or the suspicion of these cancers. Enrolled patients were to receive a total of three 5cm x 5cm x 0.5cm bupivacaine—collagen sponges implanted at specified layers in the wound prior to wound closure. Each bupivacaine-collagen sponge was impregnated with mg/cm?’ of bupivacaine.
.PATIENT SELECTION CRITERIA Inclusion Aged between 18 to 60 years -95 Kg in weight Able and willing to comply with pain relief regime outlined in the protocol Exclusion Known hypersensitivity to amide local anaesthetics, NSAIDS, opioids and bovine collagen Cardiac arrhythrnias or AV conduction disorders Concomitant use of other amide local anaesthetics Concomitant use of anti~a1'rhythmics e.g. Amiodarone Concomitant use of propanolol Spinal blockade Concomitant use of strong/moderate CYP3A4 inhibitors or inducers e.g. macrolide antibiotics, grapefruit juice etc.
Previous major surgery in last 6 months Hepatic impairment Any clinically significant unstable cardiac, neurological, immunological, renal or haematological disease or any other condition that in the opinion of the Investigator would interfere with the course of the study Participation in a clinical trial using an Investigational Product in the previous 6 months Haemodynamically unstable at any point in the previous 4 weeks Requirement for blood transfusion in the previous 3 months Haemoglobin below 10 g/dL OBJECTIVES Objectives To investigate the potential analgesic effect of the bupivacaine—collagen sponge in the hysterectomy wound. 0 To investigate the morphine sparing effect of using bupivacaine-collagen sponge as part of the post-operative analgesia regimen. 0 To evaluate trends in numerical rating scales of pain intensity The study outcomes comprise: 0 Visual analogue pain rating scale (V AS) Morphine sparing effect STUDY DURATION
[0064] Screening assessments (informed consent, medical history, vital signs, 12-lead electrocardiogram, clinical biochemistry and haematology, urinalysis and demographics) took place between 1 and 14 days prior to administration of the bupivacaine-collagen sponge. Baseline (0 hours) procedures included allocation of study number, baseline pain scoring and implantation of the sponge. Follow-up procedures took place over 96 hours post implantation. A follow-up call was performed 8 days after implantation.
METHODOLOGY Safety Analysis
[0065] Vital signs and clinical assessment for signs of systemic bupivacaine toxicity were repeated at 30 mins, 1, 1.5, 2, 3, 4, 5, 6, 9, 12 & 96 hours. A follow-up call was to be performed 8 days after surgery to check if the patient was suffering from any adverse event or is experiencing any problem with the wound. Concomitant medication (including doses of morphine and other pain medications) was collected from the screening until assessment 18.
TABLE 1: Safety Blood and Urinalysis Tests Haematology Blood Chemistry Urinalysis Haematocrit Sodium Total bilirubin pH Haemoglobin Chloride Direct bilirubin Protein RBC Magnesium ALT (SGPT) Glucose Platelet Potassium AST (S GOT) Occult blood WBC with differential Calcium Ferritin PT Bicarbonate Transferritin PTT Glucose GGT Phosphorus Iron Uric Acid C-reactive protein Creatinine Total Cholesterol Blood Urea Nitrogen Triglycerides (BUN) Efficacy Evaluations
[0066] Pain scoring using a visual analogue score (VAS) was used to assess the patient’s experience ofpain at 1, 1.5, 2, 3, 6, 9, 12, 18*, 24, 36, 48, 72 & 96 hour timepoints.
Following surgery, patients were provided with PRN (per re nata, as needed) morphine via a PCA pump. Patient demand for morphine was recorded. The pain assessment at 18 hours was optional so that sleep is not disturbed.
LIST OF ABBREVIATIONS AE Adverse Events AUCM Area under the plasma concentration-time curve from time zero to time t (time of last quantifiable plasma concentration) AUC;nfArea under the plasma concentration-time curve from time zero to infinity Cmax LOQ Limit of quantification Maximum plasma concentration PCA Patient Controlled Analgesia PRN per re nata (as needed) tlag Lag—time tmax Time of maximum plasma concentration ty, Terminal half life &2 Terminal phase rate constant VAS Visual Analogue Scale Pain Control Medication (Supplemental to the Bupivacaine-Collagen Sponge)
[0067] At induction, patients received 50-75ug fentanyl. Following catheterisation and prior to the commencement of surgery, they also received 100 mg diclofenac rectally.
Intra-operatively, morphine was administered intravenously as required to maintain adequate levels of analgesia. Post-operatively, patients received 1 g paracetamol six hourly, 50 mg diclofenac every 8 hours, with a maximum of 3 doses in any 24 hours, and morphine PRN (per re nata, as needed) using a patient controlled analgesia pump.
Concomitant Therapy Permitted Concomitant Therapies
[0068] In order to ensure conformity in the amount of analgesia received post-opcratively, all patients received 1000 mg paracetamol at 6 hourly intervals and 50 mg diclofenac at 8 hourly intervals and morphine PRN using a PCA pump.
Prohibited Concomitant Therapies {0069] All analgesics were stopped for 24 hours prior to the study commencing. In addition, the following therapies (Table 2) were not administrated concomitantly with the implantation of the bupivacaine-collagen sponge.
TABLE 2: Prohibited Concomitant Therapies Strong or Moderate Inhibitors of the Inducers of the CYP3A4 Pathway CYP3A4 Pathway Grapefruit juice troglitazone Methadone phenytoin Itraconazole rifampicin Ketoconazole carbamazepine Fluconazole phenobarbal Clarithromycin St. John’s Wort (hypericin) Erythromycin Nefazodone F luoxetine Ritonavir Indinavir Nelfinavir Arnprenavir Saquinavir RESULTS Safety Analysis Current Safety Data from Ongoing Clinical Study Pt AB Description Causality Severity Treatment Outcome No.
Urine infection Not Moderate (No antibiotics) Resolved by Available Day 8 001 Nausea on days Unlikely Moderate Odensatron & Resolved by 1 and 2 cyclizine Day 8 001 Visual Possible Moderate none Resolved by disturbances Day 8 002 Nausea Not Mild (None) Resolved Available Increased BP lst Not _ (Details (Details awaited) Resolved by few hours Available awaited) Day 2 considered normal for patient & not significant Anemia HB 11 Not Moderate 2 units blood HB 10 to 8 Available transfusion Urine infection Not Moderate Augmentin 625 mg (Details Available TDS 5 days awaited) Efficacy Analysis
[0070] Efficacy of the bupivacaine-collagen sponge was determined by use of visual analogue scales and by the morphine sparing effect.
Pain Scoring {Visual Analogue Pain Rating Scale]
[0071] Pain scoring using a visual analogue scale ranging from 0 (no pain) to 100 (worst imaginable pain). These were assessed from 1 hour onwards according to the assessment schedule. Individual pain scores were listed for each assessment time.
Morphine Sparing
[0072] Patients were given 6 hourly doses of 1000 mg paracetamol, 8 hourly doses of 50 mg diclofenac and morphine PRN via patient controlled analgesia (PCA) pump. The doses of morphine demanded by each patient over the first 24 hours of the treatment period were recorded and compared to historical data in the literature. Total doses of morphine required over the treatment period were listed for each patient.
[0073] 4 subjects have, to date, been enrolled in this study. The total morphine usage and pain scores (Visual Analog Scale of 0 to 100mm where 0 is no pain and 100 is the Worst imaginable pain) that have been reported by these 4 subjects are presented in Table 3.
TABLE 3 Ongoing Clinical Study Summary of Morphine Usage and Pain Scores of Subjects Enrolled in Patient No. 001 002 003 004 45 19 Date of enrollment 26-Jan-07 2—Feb-07 8-Feb—07 8-Feb-07 (date of surgery) Total Amount of Morphine 28 7 0 1 consumed (mgs) over first 24 hours post-op Pain scores (V AS) 1h 68 45 2 19 (mm) 1.5h 49 34 7 19 2h 43 56 1 3 3 0 3h 43 65 13 24 6h 1 6 5 0 10 9h 4 2 0 12 12h 4 0 6 6 18h Not done 0 4 6 24h 14 3 2 4 36h 24 2 3 0 48h 2 0 0 0 72h 1 9 0 0 96h 0 6 0 0 Day of discharge 5 4 5 5 [007 4] Table 3 shows that the average postoperative morphine consumption was 9 mg over the first 24 hours post—op. In contrast, the average postoperative morphine consumption using bupivacaine infiltration in both deep and superficial layers of the wound after abdominal hysterectomy was 54mg (Klein et al, 2000) and 44mg (N g et al, 2002) and narcotic consumption during the first 24 hours varied from 35 to 62 mg (Gupta, 2004).
[0075] The invention is not limited to the embodiments described and exemplified herein, which may be modified and amended without departing from the scope of the present invention. While the invention has been described above with reference to specific embodiments thereof, it is apparent that many changes, modifications, and variations can be made without departing from the inventive concept disclosed herein. Accordingly, it is intended to embrace all such changes, modifications, and variations that fall within the spirit and broad scope of the appended claims.
REFERENCES: Gupta A, Perniola A, Axelsson K, Thorn SE, Crafpprd K, and Rawal N (2004).
Postoperative pain after abdominal hysterectomy: a double-blind comparison between placebo and local anesthetic infused intraperitoneally. Anesth Analg 99: 1 173-1 179.
Leung CC, Chan YM, Ngai SW, et al (2000). Effect of pre-incision skin infiltration on post-hysterectomy pain—a double-blind randomized controlled trial. Anaesth Intensive Care 2000;28:510-516.
Ng A, Swami A, Smith G, et al (2002). The analgesic effects of intraperitoneal and incisional bupivacaine with epinephrine after total abdominal hysterectomy. Anesth Analg 2002;95:158-162.
Sinclair et al, 1996 Postoperative pain relief by topical lidocaine in the surgical wound of hysterectomized patients; Acta Anaesthesiologiea Scandinavica 40: 589-594 Hannibal et al, 1996 Preoperative wound infiltration with bupivacaine reduces early and late opioid requirements after hysterectomy. British Journal of Anaethesiology 83: 376-381 Cobby et al, 1997 Wound infiltration with local anaesthetic after abdominal hysterectomy British Journal of Anaethesiology :78: 431-432 Victory et al, 1995 Effect of preincision versus postincision infiltration with bupivacaine on postoperative pain Journal of Clinical Anesthesia 7: 192-196 Bartholdy et al, 1994 Preoperative infiltration of the surgical area enhances postoperative analgesia of a combined low-dose epidural bipivacaine and morphine regimen after upper abdominal surgery. Acta Anaesthesiologica Scandinavica 38: 262-265 Mainiche et al, 1998 A qualitative systemic review of incisional local anaesthesia for postoperative pain relief after abdominal operations; British Journal of Anaesthesia; 81: 377-383 Klein et al, 2000 Infiltration of the abdominal wall with local anaesthetic afier total abdominal hysterectomy with no opioid-sparing effect; British Journal of Anaesthesia 84 (2): 248-9
Claims (23)
1. A drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device consisting essentially of a fibrillar collagen sponge matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.
2. The drug delivery device of Claim 1, wherein the at least one drug substance is present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about two days after administration.
3. The drug delivery device of Claim 1, wherein the at least one drug substance is present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about three days after administration.
4. The drug delivery device of Claim 1, wherein the at least one drug substance is an amino amide anesthetic selected from the group comprising Bupivacaine, Levobupivacaine, Lidocaine, Mepivacaine, Prilocaine, Ropivacaine, Articaine, Trimecaine and their salts and prodrugs.
5. The drug delivery device of Claim 1, wherein the at least one drug substance is an amino amide anesthetic selected from bupivacaine and salts and prodrugs thereof.
6. The drug delivery device of Claim 1, wherein the fibrillar collagen matrix is a Type 1 collagen matrix.
7. The drug delivery device of Claim 1, wherein the fibrillar collagen matrix is a Type I collagen matrix and the at least one drug substance is an amino amide anesthetic selected from bupivacaine and salts and prodrugs thereof.
8. The drug delivery device of Claim 7, wherein the drug delivery device comprises a plurality of collagen sponges, each collagen sponge containing about 3 .6 to about 8.0mg/cm3 type I collagen and about 2.0 to about 6.0mg/cm3 bupivacaine hydrochloride.
9. The drug delivery device of Claim 7, wherein the drug delivery device comprises a plurality of collagen sponges, each collagen sponge containing about 5.6rng/cm3 type I collagen and about 4.0mg/cms bupivacaine hydrochloride. 23
10. Use of a fibrillar collagen sponge matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen sponge matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration a for the manufacture of a drug delivery device for providing iocal analgesia, local anesthesia or nerve blockade in the human or animal in need thereof, the use comprising administering the drug delivery device at a site in the human or animal in need thereof .
11. The use of Claim 10, wherein the at least one drug substance is present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about two days after administration.
12. The use of Claim 10, wherein the at least one drug substance is present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about three days after administration.
13. The use of Claim 10, wherein the at least one drug substance is an amino amide anesthetic selected from the group comprising Bupivacaine, Levobupivacaine, Lidocaine, Mepivacaine, Prilocaine, Ropivacaine, Articaine, Trimecaine and their salts and prodrugs.
14. The use of Claim 10, wherein the at least one drug substance is an amino amide anesthetic selected from bupivacaine and salts and prodrugs thereof.
15. The use of Claim 10, wherein the fibrillar collagen matrix is a Type I collagen matrix.
16. The use of Claim 10, wherein the fibrillar collagen matrix is a Type I collagen matrix and the at least one drug substance is an amino amide anesthetic selected from bupivacaine and salts and prodrugs thereof.
17. The use of Claim 16, wherein the drug delivery device comprises a plurality of collagen sponges, each collagen sponge containing about 3 .6 to about 8.0mg/cm3 type I collagen and about 2.0 to about 6.0mg/cm?‘ bupivacaine hydrochloride.
18. The use of Claim 16, wherein the drug delivery device comprises a plurality of collagen sponges, each collagen sponge containing about 5.6mg/em3 type I collagen and T about 4.0mg/cm3 bupivacaine hydrochloride.
19. The use of Claim 10, wherein the use is for providing local analgesia, local anesthesia or nerve blockade in a human following laparotomy.
20. The use of Claim -10, wherein the use is for providing local ana1gesia,loca1 anesthesia or nerve blockade in a human following hysterectomy.
21. The use of Claim 17, wherein the use is for providing local analgesia, local anesthesia or nerve blockade in a human following hysterectomy.
22. The use of Claim 18, wherein the use is for providing local analgesia, local anesthesia or nerve blockade in a human following hysterectomy.
23. The use of Claim 10, wherein the drug delivery device comprises a plurality of collagen sponges and wherein one sponge is divided between areas in the surgical vault, one sponge is divided and placed across the incision in the peritoneum and one sponge is divided and placed between the sheath and skin around the incision.
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE2007/0220A IE85880B1 (en) | 2007-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
PL08719893.3T PL2139457T3 (en) | 2007-03-28 | 2008-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
PT16154811T PT3085363T (en) | 2007-03-28 | 2008-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
EP16154811.0A EP3085363B1 (en) | 2007-03-28 | 2008-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
EP08719893.3A EP2139457B1 (en) | 2007-03-28 | 2008-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
DK08719893.3T DK2139457T3 (en) | 2007-03-28 | 2008-03-28 | The drug delivery device for providing local anesthetic, LOCAL ANAESTHESIA OR nerve block |
PCT/IE2008/000035 WO2008117268A2 (en) | 2007-03-28 | 2008-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
PT87198933T PT2139457T (en) | 2007-03-28 | 2008-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
LTEP16154811.0T LT3085363T (en) | 2007-03-28 | 2008-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
DK16154811.0T DK3085363T3 (en) | 2007-03-28 | 2008-03-28 | PHARMACEUTICAL ADMINISTRATION TO PROVIDE LOCAL ANALYSIS, LOCAL ANESTHESIA OR NERVOUS BLOCKS |
ES16154811T ES2718542T3 (en) | 2007-03-28 | 2008-03-28 | A medication delivery device to provide local analgesia, local anesthesia or nerve block |
ES08719893.3T ES2582368T3 (en) | 2007-03-28 | 2008-03-28 | Medication delivery device to provide local analgesia, local anesthesia or nerve block |
SI200831641A SI2139457T1 (en) | 2007-03-28 | 2008-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
DE202008018583.1U DE202008018583U1 (en) | 2007-03-28 | 2008-03-28 | Drug delivery system for local analgesia, local anesthesia or nerve block |
TR2019/05174T TR201905174T4 (en) | 2007-03-28 | 2008-03-28 | A drug delivery device to provide local analgesia, local anesthesia or nerve blockage. |
HUE16154811A HUE043185T2 (en) | 2007-03-28 | 2008-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
JP2010500426A JP5372905B2 (en) | 2007-03-28 | 2008-03-28 | Drug delivery device for providing local analgesia, local anesthesia or nerve block |
IE20080229A IES20080229A2 (en) | 2007-03-28 | 2008-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
SI200832058T SI3085363T1 (en) | 2007-03-28 | 2008-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
PL16154811T PL3085363T3 (en) | 2007-03-28 | 2008-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
HUE08719893A HUE027803T2 (en) | 2007-03-28 | 2008-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
HRP20160743TT HRP20160743T1 (en) | 2007-03-28 | 2016-06-27 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
CY20161100677T CY1117814T1 (en) | 2007-03-28 | 2016-07-14 | MEDICINE PROVIDER TO PROVIDE LOCAL ANALYSIS, LOCAL ANESTHESIA OR NERVAL EXCLUSION |
CY20191100409T CY1121568T1 (en) | 2007-03-28 | 2019-04-12 | MEDICINE PROVISION FOR THE PROVISION OF LOCAL ANALGESIA, LOCAL ANESTHESIA OR NERVOUS EXCLUSION |
HRP20190699TT HRP20190699T1 (en) | 2007-03-28 | 2019-04-15 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE2007/0220A IE85880B1 (en) | 2007-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
Publications (2)
Publication Number | Publication Date |
---|---|
IE20070220A1 IE20070220A1 (en) | 2008-12-10 |
IE85880B1 true IE85880B1 (en) | 2011-10-26 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2139457B1 (en) | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
US8034368B2 (en) | Drug delivery device for providing local analgesia, local anesthesia or nerve blockage | |
EP1809329B1 (en) | Sustained local anesthetic composition containing saib | |
CN104958752B (en) | The treatment of degenerative joint disease | |
USRE47826E1 (en) | Drug delivery device for providing local analgesia, local anesthesia or nerve blockage | |
US20080241243A1 (en) | Drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
CA2294950C (en) | Levobupivacaine and its use | |
IE85880B1 (en) | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
IE20070220A1 (en) | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
IES85185Y1 (en) | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
IE20080229U1 (en) | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
CN111629713B (en) | Pharmaceutical composition for treating postoperative pain | |
WO2007135123A2 (en) | Mirtazapine for the treatment of neuropathic pain | |
WO2021232157A1 (en) | Sustained release pharmaceutical composition | |
EA044480B1 (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF POSTOPERATIVE PAIN AND METHOD FOR PREPARING SUCH COMPOSITION | |
EP1762239A1 (en) | Lofexidine for intraspinal administration | |
MXPA00000397A (en) | Levobupivacaine and its use |